Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 217

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 217
---
, among other things, that prior to the Business Combination, APx may not issue additional shares that would entitle the holders thereof to (i) receive funds from the Trust Account or (ii) vote as a class with the Public Shares on the Business Combination. These provisions of the Existing Governing Documents, like all provisions of the Existing Governing Documents, may be amended with a shareholder vote. The issuance of additional ordinary shares or preference shares: •may significantly dilute the equity interest of investors in the IPO; •may subordinate the rights of holders of ordinary shares if preference shares are issued with rights senior to those afforded to the ordinary shares; •could cause a change in control if a substantial number of ordinary shares or preference shares are issued; and •may adversely affect prevailing market prices for the SPAC Units, Public Shares and Public Warrants. To the extent that APx enters into an agreement to issue a substantial amount of shares in connection with the Closing following the mailing of this proxy statement/prospectus, APx shall, no later than five days prior to the Special Meeting, file a Current Report on Form 8 -Kdescribing such agreement(s). APx may amend the terms of the APx Warrants in a manner that may be adverse to holders of Public Warrants with the approval by the holders of at least 50% of the then outstanding Public Warrants. As a result, the exercise price of your Warrants could be increased, the exercise period could be shortened and the number of ordinary shares purchasable upon exercise of a Warrant could be decreased, all without your approval. The APx Warrants are issued in registered form under the SPAC Warrant Agreement, which provides that the terms of the APx Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval by the holders of at least 65% of the then outstanding Public Warrants to make any change that adversely affects the interests of the registered holders of Public Warrants. Accordingly, APx may amend the terms of the Public Warrants in a manner adverse to a holder if holders of at least 65% of the then outstanding Public Warrants approve of such amendment. Although APx’s ability to amend the terms of the Public Warrants with the consent of at least 65% of the then outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the APx Warrants, convert the APx